Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P0C263

UPID:
SBK2_HUMAN

ALTERNATIVE NAMES:
SH3-binding domain kinase family member 2; Sugen kinase 69

ALTERNATIVE UPACC:
P0C263

BACKGROUND:
The Serine/threonine-protein kinase SBK2, known alternatively as SH3-binding domain kinase family member 2 and Sugen kinase 69, is integral to the phosphorylation processes within cells. This enzyme's activity is pivotal for the regulation of protein functions through the modification of serine and threonine residues, essential for cellular communication and function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Serine/threonine-protein kinase SBK2 holds promise for uncovering novel therapeutic approaches. Given its central role in phosphorylation and signaling pathways, targeting SBK2 could lead to breakthroughs in treating conditions associated with these pathways' dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.